FLT3

Cluster of differentiation antigen 135; CD135; Fms like tyrosine kinase 3

FLT3 (Fms-like tyrosine kinase 3, CD135) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. FLT3 is the receptor for the cytokine Flt3 ligand (FLT3L). FLT-3 is expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. The FLT3 gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). Besides, high levels of wild-type FLT3 have been reported for blast cells of some AML patients without FLT3 mutations. These high levels may be associated with worse prognosis. Signaling through FLT3 plays a role in cell survival, proliferation, and differentiation. FLT3 is important for lymphocyte (B cell and T cell) development, but not for the development of other blood cells. Two cytokines that down modulate FLT3 activity are TNF-Alpha and TGF-Beta.

FLT3 Inhibitors

(E/Z)-Zotiraciclib

((E/Z)-TG02; (E/Z)-SB1317) Cat. No.: HY-15166

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of **CDK2**, **JAK2**, and **FLT3**. (E/Z)-Zotiraciclib ((E/Z)-TG02) can be used for the research of cancer.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-Zotiraciclib citrate

((E/Z)-TG02 citrate; (E/Z)-SB1317 citrate) Cat. No.: HY-15166B

(E/Z)-Zotiraciclib citrate is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Zotiraciclib hydrochloride

((E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride) Cat. No.: HY-15166A

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(R)-3-Hydroxy Midostaurin

((R)-CGP52421) Cat. No.: HY-108263B

(R)-3-Hydroxy Midostaurin ((R)-CGP52421) is a potent kinases inhibitor. (R)-3-Hydroxy Midostaurin is a major metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (R)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-3-Hydroxy Midostaurin

((S)-CGP52421) Cat. No.: HY-108263A

(S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a potent kinases inhibitor with **IC_{50}** values of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)-SU5614

Cat. No.: HY-18952A

(Z)-SU5614 is a potent **FLT3** inhibitor and selectively induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

3-Hydroxy Midostaurin

(CGP52421) Cat. No.: HY-108263

3-Hydroxy Midostaurin (CGP 52421), a metabolite of PKC412, effectively inhibits **FMS-like tyrosine kinase-3 (FLT3)** autophosphorylation with **IC_{50}**s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively. 3-Hydroxy Midostaurin is less selective but more cytotoxic than PKC412.



Purity: 97.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

4SC-203

Cat. No.: HY-19897

4SC-203 is a potent **multikinase** inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

5'-Fluoroindirubinoxime

(5'-FIO) Cat. No.: HY-103464

5'-Fluoroindirubinoxime (5'-FIO, compound 13), an Indirubin (HY-N0117) derivative, is a potent **FLT3** inhibitor, with an **IC_{50}** of 15 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with **K_d**s of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AKN-028

Cat. No.: HY-118304

AKN-028 is an orally active and potent **FLT3 tyrosine kinase** inhibitor (IC_{50} = 6nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Altiratinib

(DCC-2701)

Cat. No.: HY-B0791

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC_{50}s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AMG 925

Cat. No.: HY-15889

AMG 925 is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMG 925 HCl

Cat. No.: HY-15889A

AMG 925 HCl is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

AST 487

(NVP-AST 487)

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT9283

Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (IC_{50}s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

ATH686

Cat. No.: HY-15003

ATH686 is a potent, selective and ATP-competitive **FLT3** inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of **apoptosis** and cell cycle inhibition. ATH686 has antileukemic effects.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 96.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BPR1J-097

Cat. No.: HY-13537

BPR1J-097 is a novel potent **FLT3** inhibitor with an IC_{50} of 11nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BPR1J-097 Hydrochloride

Cat. No.: HY-13537A

BPR1J-097 Hydrochloride is a novel and potent **FLT3** inhibitor with an IC_{50} of 11nM.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BPR1K871

(DBPR114)

Cat. No.: HY-100865

BPR1K871 is a potent and selective dual **FLT3/AURKA** inhibitor with IC_{50}s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BSc5371

Cat. No.: HY-111545

BSc5371 is a potent and irreversible **FLT3** inhibitor, with K_ds of 1.3, 0.83, 1.5, 5.8 and 2.3 nM for mutant FLT3(D835H), FLT3(ITD, D835V), FLT3(ITD, F691L), FLT3-ITD and wild type FLT3wt, respectively. BSc5371 is cytotoxic to FLT3-dependent cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CA-4948

Cat. No.: HY-135317

CA-4948 is a potent **IRAK4/FLT3** inhibtor with anti-tumor activity.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib-d4

(XL184-d4; BMS-907351-d4)

Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

CCT241736

Cat. No.: HY-18161

CCT241736 is a potent and orally bioavailable dual **FLT3** and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC_{50}, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cenisertib

(AS-703569; R-763)

Cat. No.: HY-13072

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHIR-124

Cat. No.: HY-13263

CHIR-124 is a potent and selective **Chk1** inhibitor with IC_{50} of 0.3 nM, and also potently targets **PDGFR** and **FLT3** with IC_{50}s of 6.6 nM and 5.8 nM.



Purity: 96.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crenolanib

(CP-868596)

Cat. No.: HY-13223

Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases **FLT3** and **PDGFRα/β** with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Crotonoside

(Isoguanosine)

Cat. No.: HY-N0071

Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits **FLT3** and **HDAC3/6**, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML.



Purity: 98.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate)

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate)

Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E6201

(ER-806201)

Cat. No.: HY-15496

E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of **MEK1** and **FLT3**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

FLT3-IN-10

Cat. No.: HY-134481

FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (**FLT3**). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-11

Cat. No.: HY-143894

FLT3-IN-11 (compound 30) is a potent, selective and orally active **FLT3 kinase** inhibitor with **IC_{50}**s of 7.22 nM and 4.95 nM for **wild-type FLT3** and **FLT3-D835Y**, respectively. FLT3-IN-11 high selectivity for FLT3 over c-KIT (>1000-fold).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-12

Cat. No.: HY-143895

FLT3-IN-12 is a potent, selective and orally active **FLT3 kinase** inhibitor with **IC_{50}**s of 1.48 nM and 2.87 nM for **FLT3-WT** and **FLT3-D835Y**, respectively. FLT3-IN-12 possesses high selectivity over c-KIT (>1000-fold).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-14

Cat. No.: HY-144777

FLT3-IN-14 is a potent **FLT3** inhibitor with **IC_{50}**s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and **apoptosis**. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-15

Cat. No.: HY-146886

FLT3-IN-15 is a highly potent and orally active **FLT3** inhibitor with **IC_{50}**s of 0.87 nM and 0.32 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-15 can be used for researching acute myeloid leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3-IN-2

Cat. No.: HY-18744

FLT3-IN-2 is a FLT3 inhibitor with IC50 of 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FLT3-IN-3

Cat. No.: HY-112145

FLT3-IN-3 is a potent **FLT3** inhibitor with **IC_{50}**s of 13 and 8 nM for **FLT3 WT** and **FLT3 D835Y**, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-4

Cat. No.: HY-128571

FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (**FLT3**; **IC_{50}**=7 nM) inhibitor for treating acute myelogenous leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3-IN-6

Cat. No.: HY-128572

FLT3-IN-6 is a potent and selective inhibitor of **FLT3-ITD** (FLT3 mutation) with an **IC_{50}** of 1.336 nM.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FLT3/CDK4-IN-1

Cat. No.: HY-115904

FLT3/CDK4-IN-1 is a potent, high selective and orally active **FLT3/CDK4** dual inhibitor (**IC_{50}**=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/D835Y-IN-1

Cat. No.: HY-143434

FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective **FLT3** and **FLT3/D835Y** inhibitor, with IC_{50} values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLT3/TrKA-IN-1

Cat. No.: HY-146749

FLT3/TrKA-IN-1 is a potent **FLT3/TrKA** dual kinase inhibitor with the IC_{50}s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FN-1501

Cat. No.: HY-111361

FN-1501 is a potent inhibitor of **FLT3** and **CDK**, with IC_{50}s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib

(R788)

Cat. No.: HY-13038A

Fostamatinib (R788) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib Disodium

(R788(Disodium))

Cat. No.: HY-13038

Fostamatinib Disodium (R788 Disodium) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib disodium hexahydrate

(R788 disodium hexahydrate)

Cat. No.: HY-13038B

Fostamatinib (R788) disodium hexahydrate is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM).



Purity: 98.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fostamatinib-d9

(R788-d9)

Cat. No.: HY-13038AS

Fostamatinib-d9 (R788-d9) is the deuterium labeled Fostamatinib. Fostamatinib (R788) is the oral prodrug of the active compound R406. R406 is an orally available and competitive **Syk/FLT3** inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G-749

Cat. No.: HY-12333

G-749 is a potent, oral active and ATP competitive **FLT3** inhibitor, with IC_{50}s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. G-749 can be used for the research of drug resistance for acute myeloid leukemia (AML).



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Gandotinib

(LY2784544)

Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib

(ASP2215)

Cat. No.: HY-12432

Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: 99.55%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib hemifumarate

(ASP2215 hemifumarate) Cat. No.: HY-12432A

Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive **FLT3/AXL** inhibitor with **IC_{50}** of 0.29 nM/0.73 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib-d3

(ASP2215-d3) Cat. No.: HY-12432S

Gilteritinib-d3 (ASP2215-d3) is the deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with **IC_{50}**s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gilteritinib-d8

(ASP2215-d8) Cat. No.: HY-12432S1

Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HM43239

Cat. No.: HY-145015

HM43239 is an orally active and selective **FLT3** inhibitor with **IC_{50}**s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HP1142

Cat. No.: HY-145691

HP1142 is a potent and selective inhibitor of **FLT3** receptor tyrosine kinase (FLT3/ITD mutation). HP1142 is a benzoimidazole scaffold-based compound. HP1142 has the potential for the research of FLT3/ITD leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HP1328

Cat. No.: HY-145690

HP1328 is a potent inhibitor of **FLT3** receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypothemycin

Cat. No.: HY-107417

Hypothemycin, a fungal polyketide, is a multikinase inhibitor with **K_i**s of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for **VEGFR2/VEGFR1**, **MEK1/MEK2**, **FLT-3**, **PDGFRβ/PDGFRα**, and **ERK1/ERK2**, respectively.



Purity: 96.10%
Clinical Data: No Development Reported
Size: 1 mg

JAK2-IN-7

Cat. No.: HY-131906

JAK2-IN-7 is a selective **JAK2** inhibitor with **IC_{50}**s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3^{V617F} cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK2/FLT3-IN-1

Cat. No.: HY-130247

JAK2/FLT3-IN-1 is a potent and orally active dual **JAK2/FLT3** inhibitor with **IC_{50}** values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2/FLT3-IN-1 TFA

Cat. No.: HY-130247A

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual **JAK2/FLT3** inhibitor with **IC_{50}** values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JNJ-47117096 hydrochloride

(MELK-T1 hydrochloride)

Cat. No.: HY-12420

JNJ-47117096 hydrochloride is potent and selective **MELK** inhibitor, with an IC_{50} of 23 nM, also effectively inhibits **Flt3**, with an IC_{50} of 18 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

K783-0308

Cat. No.: HY-115906

K783-0308 is a potent and selective dual inhibitor of **FLT3** and **MNK2** with IC_{50} values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC_{50}=10.5 μM) and MV-4-11 (IC_{50}=10.4 μM) cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KG5

Cat. No.: HY-15198

KG5 is an orally active dual **PDGFRβ** and **B-Raf** allosteric inhibitor. KG5 also inhibits **Flt3**, **KIT** and **c-Raf**. KG5 has anticancer, antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL**^{T315I} and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LBW242

Cat. No.: HY-15519

LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic **IAP** inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lestaurtinib

(CEP-701; KT-5555)

Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is an ATP-competitive multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits **JAK2**, **FLT3** and **TrkA** with IC_{50}s of 0.9, 3 and less than 25 nM, respectively.



Purity: 99.92%
Clinical Data: Phase 3
Size: 5 mg

Linifanib

(ABT-869; AL-39324)

Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

LT-850-166

Cat. No.: HY-139619

LT-850-166 is a potent **FLT3** inhibitor with the capacity of overcoming a variety of FLT3 mutations.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Luxeptinib

(CG-806)

Cat. No.: HY-139535

Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent **pan-FLT3/pan-BTK** inhibitor. Luxeptinib induces cell cycle arrest, **apoptosis** or **autophagy** in acute myeloid leukemia cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MAX-40279

Cat. No.: HY-145723

MAX-40279 is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemiadipate

Cat. No.: HY-145723C

MAX-40279 hemiadipate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemifumarate

Cat. No.: HY-145723B

MAX-40279 hemifumarate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hydrochloride

Cat. No.: HY-145723A

MAX-40279 hydrochloride is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Merestinib

(LY2801653)

Cat. No.: HY-15514

Merestinib (LY2801653) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride

(LY2801653 dihydrochloride)

Cat. No.: HY-15514A

Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable **c-Met** inhibitor (K_i=2 nM) with anti-tumor activities.



Purity: 99.36%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MRX-2843

(UNC2371)

Cat. No.: HY-101549

MRX-2843 (UNC2371) is an orally active, ATP-competitive dual **MERTK** and **FLT3** tyrosine kinases inhibitor (TKI) with enzymatic IC_{50}s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively.



Purity: 99.70%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

OTS447

Cat. No.: HY-144869

OTS447 is a potent **FLT3** inhibitor with an IC_{50} of 21 nM (WO2012016082A1, compound 335).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pacritinib

(SB1518)

Cat. No.: HY-16379

Pacritinib (SB1518) is a potent inhibitor of both wild-type **JAK2** (IC_{50}=23 nM) and **JAK2**^{V617F} mutant (IC_{50}=19 nM). Pacritinib also inhibits **FLT3** (IC_{50}=22 nM) and its mutant **FLT3**^{D835Y} (IC_{50}=6 nM).



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC FLT-3 degrader 1

Cat. No.: HY-114323

PROTAC FLT-3 degrader 1 is a **von Hippel-Lindau**-based PROTAC **FLT-3** internal tandem duplication (**ITD**) degrader with an IC_{50} 0.6 nM. Anti-proliferative activity; apoptosis induction.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Quizartinib

(AC220)

Cat. No.: HY-13001

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II **FLT3 tyrosine kinase** inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC_{50}s of 4.2 and 1.1 nM, respectively.



Purity: 99.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

R406

Cat. No.: HY-12067

R406 is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC_{50} of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 96.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

R406 free base

Cat. No.: HY-11108

R406 free base is an orally available and competitive **Syk/FLT3** inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC_{50} of 41 nM, measured at an ATP concentration corresponding to its K_m value.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rebastinib

(DCC-2036)

Cat. No.: HY-13024

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive **Bcr-Abl** inhibitor for $Abl1^{WT}$ and $Abl1^{T315I}$ with IC_{50}s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ripretinib

(DCC-2618)

Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SEL24-B489

Cat. No.: HY-120758

SEL24-B489 is a potent, type I, orally active, dual **PIM** and **FLT3-ITD** inhibitor, with K_d values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sitravatinib

(MGCD516; MG-516)

Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.59%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate)

Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

SKLB4771

(FLT3-IN-1)

Cat. No.: HY-12960

SKLB4771 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM. IC50 value: 10 nM (in vitro) Target: in vitro: SKLB4771 inhibited FLT3 phosphorylation in a dose-dependent manner.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sorafenib

(Bay 43-9006)

Cat. No.: HY-10201

Sorafenib (Bay 43-9006) is a potent and orally active **Raf** inhibitor with IC_{50}s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively. Sorafenib is a multikinase inhibitor with IC_{50}s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for **VEGFR2**, **VEGFR3**, **PDGFRβ**, **FLT3** and **c-Kit**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib Tosylate

(Bay 43-9006 Tosylate)

Cat. No.: HY-10201A

Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active **Raf** inhibitor with IC_{50}s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Sorafenib-13C,d3

Cat. No.: HY-10201S2

Sorafenib-13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active **Raf** inhibitor with IC_{50}s of 6 nM and 20 nM for **Raf-1** and **B-Raf**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sorafenib-d3

(Bay 43-9006-d3; Donafenib)

Cat. No.: HY-10201S

Sorafenib-d3 (Bay 43-9006-d3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: 99.57%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sorafenib-d4

(Bay 43-9006-d4)

Cat. No.: HY-10201S1

Sorafenib-d4 (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC_{50}s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-659

Cat. No.: HY-100867

TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of **spleen tyrosine kinase (SYK)** and **fms related tyrosine kinase 3 (FLT3)**, with an IC_{50} of 3.2 nM and 4.6 nM for SYK and FLT3, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

TAK-659 hydrochloride

Cat. No.: HY-100867A

TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of **spleen tyrosine kinase (SYK)** and **fms related tyrosine kinase 3 (FLT3)**, with an IC_{50} of 3.2 nM and 4.6 nM for SYK and FLT3, respectively.



Purity: 99.91%
Clinical Data: Phase 2
Size: 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tandutinib

(MLN518; CT53518)

Cat. No.: HY-10202

Tandutinib (MLN518) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tandutinib hydrochloride

(MLN518 hydrochloride; CT53518 hydrochloride)

Cat. No.: HY-10202A

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the **FLT3** with an IC_{50} of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with IC_{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).



Purity: 98.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

TCS 359

Cat. No.: HY-13907

TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent and selective **FLT3** inhibitor with an IC_{50} of 42 nM. TCS 359 inhibits MV4-11 cell proliferation with an IC_{50} of 340 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TG101209

Cat. No.: HY-10410

TG101209 is a selective **JAK2** inhibitor with IC_{50} of 6 nM, less potent to **Flt3** and **RET** with IC_{50} of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tyrphostin AG1296

(AG1296)

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an IC_{50} of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC2025

Cat. No.: HY-12344

UNC2025 is a potent, ATP-competitive and highly orally active **Mer/Flt3** inhibitor with IC_{50} values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC_{50}= 122 nM; K_i = 13.3 nM).



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC2025 hydrochloride

Cat. No.: HY-12344A

UNC2025 hydrochloride is a potent, ATP-competitive, and highly orally active **Mer/Flt3** inhibitor with IC_{50} values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC_{50}= 122 nM; K_i = 13.3 nM).



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC4203

Cat. No.: HY-124502

UNC4203 is a potent, orally available and highly selective **MERTK** inhibitor, with IC_{50}s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC5293

Cat. No.: HY-132200

UNC5293 is a **MERTK**-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC_{50}=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg